Amgen's Trading Volume Drops 34.1% to $554 Million Ranking 149th in Market

On June 27, 2025, Amgen's trading volume reached $554 million, a 34.1% decrease from the previous day, ranking 149th in the day's stock market. Amgen's stock price fell by 0.75%, marking the second consecutive day of decline, with a total decrease of 1.18% over the past two days.

Amgen is among several pharmaceutical companies racing to develop the next breakthrough weight loss drug, aiming to capture a share of the rapidly growing weight loss drug market. The company's experimental obesity treatment, MariTide, recently completed a Phase 2 trial, showing promising results with up to 20% weight loss.

Piper Sandler reiterated its "overweight" rating on Amgen and adjusted the price target to $328, indicating an 18.8% upside from the current price. This adjustment comes after the firm previously cut its price target from $329 to $328, maintaining an "overweight" rating.